Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201734 · ClinicalTrials.gov registry record · Phase 1
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00201734 is a Phase 1 study that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 57 participants.
The verdict
NCT00201734, a Phase 1 study, was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin.
Interventions
- DRUG Carboplatin
- DRUG Capecitabine
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2005-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201734
The ClinicalTrials.gov registry entry for NCT00201734 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00201734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00201734 about?
NCT00201734 is a clinical study titled "Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary". This study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin.
What is the current status of trial NCT00201734?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2005-06. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00201734?
The interventions under investigation include: Carboplatin (DRUG), Capecitabine (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00201734?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.